Clinical trial harmonisation needed, but pharma wary of EU project
This article was originally published in Scrip
Pharmaceutical companies are wary of participating in a voluntary pilot project run by the Heads of Medicines Agencies, which aims to harmonise the procedure for the assessment of multinational clinical trial applications made in EU member states, delegates heard at the recent European Medicines Agency/Topra meeting.
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.